Grade III to IV toxic effects of 131I-labeled anti-CD20 (tositumomab) antibody, etoposide, and CTX followed by autologous stem-cell transplantation in patients with relapsed B-cell lymphomas, according to dose level of therapy
| Toxic effect . | Dose levels 0-2 (n = 21; 40% of total) . | Dose level 3 (n = 23; 44% of total) . | Dose level 4 (n = 8; 15% of total) . |
|---|---|---|---|
| Infections3-150 | 1 (5) | 2 (9) | 1 (12) |
| Hepatic | 1 (5) | 0 | 0 |
| Mucositis | 1 (5) | 0 | 0 |
| Thyroid | 0 | 0 | 0 |
| GI | 0 | 1 (4) | 1 (12) |
| Renal3-150 | 0 | 1 (4) | 0 |
| Cardiac3-150 | 0 | 0 | 0 |
| Pulmonary | 0 | 3 (13) | 0 |
| CNS | 0 | 0 | 1 (12) |
| Any grade III-IV toxic effect | 2 (9.5) | 4 (17) | 2 (25) |
| Toxic effect . | Dose levels 0-2 (n = 21; 40% of total) . | Dose level 3 (n = 23; 44% of total) . | Dose level 4 (n = 8; 15% of total) . |
|---|---|---|---|
| Infections3-150 | 1 (5) | 2 (9) | 1 (12) |
| Hepatic | 1 (5) | 0 | 0 |
| Mucositis | 1 (5) | 0 | 0 |
| Thyroid | 0 | 0 | 0 |
| GI | 0 | 1 (4) | 1 (12) |
| Renal3-150 | 0 | 1 (4) | 0 |
| Cardiac3-150 | 0 | 0 | 0 |
| Pulmonary | 0 | 3 (13) | 0 |
| CNS | 0 | 0 | 1 (12) |
| Any grade III-IV toxic effect | 2 (9.5) | 4 (17) | 2 (25) |
Values are numbers (percentages) of patients unless otherwise indicated. Toxic effects are graded according to the scale described by Bearman et al,13 with slight modifications.
CTX indicates cyclophosphamide; GI, gastrointestinal toxicity (anorexia, nausea, vomiting, or diarrhea); CNS, central nervous system toxicity (eg, confusion or somnolence).
Patients who died of sepsis syndromes with secondary multiple-organ failure were considered to have grade IV infections, but individual-organ toxicity is not included in the table.